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Objective: Because of the dose-dependent increase in bleeding complications, the intraoperative administration of
fibrinolytic agents is limited. This limitation impairs the efficacy of fibrinolytic therapy because low-dose fibrinolysis often
fails in the treatment of complex deep venous thrombosis (DVT). The aim of this study was to investigate the efficacy and
safety of intraoperative high-dose fibrinolytic therapy for extended DVT, which was performed with the regional
hyperthermic fibrinolytic perfusion (RHFP) technique.
Methods: From January 1993 to June 2001, in 53 patients with extended DVT, unsuccessful venous thrombectomy
(recanalization, <50%) was followed by RHFP with 0.5 mg/kg of body weight of recombinant tissue plasminogen
activator. The extent of thrombosis was documented before, during (after the surgical thrombectomy), and after
(between postoperative days 2 and 5) surgery with phlebography and was quantified with the Marder score. Intraoper-
ative and postoperative complications were recorded prospectively.
Results: After RHFP, a recanalization was achieved in 64 of 146 venous segments (43.8%) that were still occluded despite
thrombectomy. Eighty-two segments (56.2%) remained occluded. Compared with the preoperative phlebography, 32
patients (60.3%) had a successful recanalization (>50%). Eleven patients (20.8%) showed minimal and 10 patients
(18.9%) no recanalization. No lethal complications occurred. One patient (1.9%) had pulmonary embolism develop, and
two patients (3.8%) had bleeding complications develop.
Conclusion: With the intraoperative use of hyperthermia-assisted high-dose fibrinolysis, improvement of the results of
mechanical thrombectomy of extended DVT was possible. The RHFP protected against systemic side effects of the
fibrinolysis and show a high safety of application. (J Vasc Surg 2002;36:1219-24.)
The intraoperative application of fibrinolytic agents is
not without problems. Systemic side effects can occur even
with local application of the fibrinolytic agent because the
plasmin developing at the thrombus during fibrinolysis is
carried away by the blood flow and reaches the systemic
circulation. The antiplasmin pool of the systemic blood
initially prevents the activation of the fibrinolytic system by
binding the circulating plasmin to antiplasmin and thereby
inactivating it. However, this mechanism is only effective
until the maximum capacity of the antiplasmin pool is
reached, which can vary significantly in different individu-
als. When the maximum capacity is exceeded, the free
plasmin becomes effective, leading to systemic fibrinolysis,
which can result in severe and potentially lethal bleeding
complications.
The technique of isolated perfusion of an extremity
with the heart-lung machine allows the application of ag-
gressive drugs with a high local concentration of the agent
while at the same time minimizing its systemic side effects.
The concept of regional hyperthermic fibrinolytic perfusion
(RHFP) is based on the utilization of an isolated extracor-
poreal circuit, in which the efficacy of fibrinolysis is opti-
mized with hyperthermia.1 The simultaneous application
of antifibrinolytic substances into the systemic circulation is
supposed to further diminish any systemic side effects of the
fibrinolysis. In a prospective study carried out at two med-
ical centers, the efficacy and safety of RHFP were investi-
gated.
PATIENTS AND METHODS
Indication and technique of RHFP. A longitudinal
incision was performed in the groin, and the common
femoral vein was exposed and opened longitudinally.
Thrombotic occlusions of the pelvic veins were treated with
a Fogarty catheter thrombectomy with phlebographic con-
trol; in the peripheral venous segments, the thrombectomy
was performed with external compression of the lower leg
and thigh. If the mechanical thrombectomy removed less
than 50% of the thrombus load, adjunctive fibrinolysis was
initiated. Contraindications for RHFP were defined as op-
erations performed less than 14 days ago and injuries of the
affected extremety located distal to the groin access site. An
18F perfusion catheter was inserted with the tip pointing
peripherally in the venotomy that had been used for the
thrombectomy. The common femoral artery was also ex-
posed and opened crosswise, and a 12F perfusion catheter
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was inserted pointing peripherally (Fig 1). After systemic
application of 150 IU/kg of body weight of heparin, the
perfusion catheters were connected to the heart-lung ma-
chine. To interrupt collateral flow in the groin, a rubber
tourniquet was wrapped tightly around the groin and se-
cured from displacement with a Steinmann pin, which had
been inserted in the iliac crest. During the perfusion, the
extremity was warmed up to 40° C.
After the warming phase of 15 to 30 minutes, 0.5
mg/kg of body weight of recombinant tissue plasminogen
activator (rt-PA; Actilyse, Boehringer, Ingelheim, Ger-
many) were infused via the arterial line of the heart-lung
machine. Simultaneous to the application of the fibrinolytic
agent into the extracorporeal circuit, 500,000 kallikrein
inactivation units of aprotinin (Trasylol, Bayer Vital, Le-
verkusen, Germany) as an antifibrinolytic agent were in-
fused into the systemic circulation. Sixty minutes after the
start of the fibrinolysis, the perfusion was stopped and the
thrombectomy maneuvers were repeated to remove
thrombi that had been loosened by the fibrinolysis. The
blood of the perfused extremity was collected with a cell
saver and reprocessed. After perfusion with 1000 to 1500
mL of electrolyte solution to wash out any remaining
intravascular rt-PA, the extremity was refilled with the
reprocessed cell-saver blood and with preoperatively do-
nated patient blood. After removal of the perfusion cathe-
ters and closure of the cannulation sites, an arteriovenous
fistula was constructed in 21 patients, mainly in cases with
iliac venous thrombosis. In three patients, stenting of the
common iliac vein was performed. After the operation, the
patients were given intravenous heparin, and after the con-
trol phlebography on postoperative days 2 to 5, anticoag-
ulation therapy with warfarin sodium was initiated and
continued for 6 months.
Quantitative assessment of thrombus extent and
definition of recanalization success. The extent of
thrombosis was determined with the scoring system pro-
posed by Marder et al2 (Table I), which allows a quantita-
tive assessment of thrombotic occlusions seen in phlebog-
raphy. In addition, the thrombi that were retrieved during
mechanical thrombectomy were reconstructed as a
“thrombus tree.” This permitted a direct comparison with
the preoperative phlebogram and allowed a further state-
ment concerning the success rate of thrombectomy. The
anatomic sites of the thrombosis were described as venous
segments (pelvic, thigh, popliteal, calf) according to the
guidelines for reporting standards in venous disease.3 The
phlebographic studies were performed before, during (after
the mechanical thrombectomy but before RHFP) and after
(between postoperative days 2 and 5) surgery. A successful
recanalization was postulated if more than 50% of the
initially occluded venous segments were reopened. A com-
plete recanalization was defined as a reopening of more
than 90% of previously occluded venous segments.
Patients. From January 1993 to June 2001, 53 pa-
tients (23 women and 30 men; mean age, 49.1  17.1
years) with extended deep venous thrombosis (DVT; three
segments, n  29; four segments, n  24) underwent
Table I. Venographic quantification of thrombosis
(Marder score2)
Region Deep veins Score*
Pelvis  groin Iliacs 6
Common femoral 4
Thigh  knee Superficial femoral 10
Popliteal 4
Calf Anterior tibials 4 (2 each)
Posterior tibials 6 (3 each)
Peroneals 6 (3 each)
40
*Complete occlusion as indicated by nonfilling of vein; score adjusted for
partial occlusions.
Fig 1. Diagram of heart-lung machine and of cannulation sites in groin.
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RHFP. According to clinical criteria, the patients had had
symptoms consistent with occlusive DVT for a mean of
6.0  4.9 days. Nine patients (17%) had recurrent DVT
after a previous history of thrombosis. Eight cases of DVT
(15%) occurred after surgery, and three cases (6%) after a
previous trauma. In 33 cases (62%), the cause of DVT
remained unclear.
A phlegmasia cerulea dolens was found in three patients
(6%). Seven extremities (14%) had been previously sub-
jected to unsuccessful recanalization therapy (thromboly-
sis, n 3; thrombectomy, n 4). Thirteen patients (25%)
had strict contraindications against systemic fibrinolysis
(operation within last 14 days, n  8; gastrointestinal
ulcers, n  4; retinal bleeding, n  1).
After the mechanical thrombectomy, 37 (pelvic level,
n  24; thigh level, n  13) of the initially 183 occluded
venous segments had been reopened, so that 146 occluded
segments (79.8%) remained for the treatment with RHFP.
The Marder score had been lowered by the thrombectomy
from 30.9 6.0 points before surgery to 23.8 4.5 points
(77%). The mean dosage of rt-PA administered during
RHFP was 36.7  8.1 mg.
RESULTS
The RHFP led to the recanalization of 67 (thigh seg-
ments, n  14; popliteal segments, n  29; lower leg
segments, n 24) of the 146 occluded segments. In three
cases, recurrent thrombosis caused the reocclusion of three
initially successfully mechanically reopened pelvic veins, so
that a total of 64 venous segments (43.8%) were success-
fully recanalized with the RHFP. Eighty-two venous seg-
ments (56.2%) remained occluded despite RHFP. Fig 2
shows the number and the localization of the occluded
segments before and after surgery. The Marder score was
lowered from 23.8  4.5 points before RHFP to 13.4 
10.5 points (56.3%) afterwards.
With a look at the recanalization success in each patient,
a complete recanalization was achieved in 20 cases (37.7%).
A total of 23 extremities (43.4%) showed a partial recana-
lization, of which 11 extremities (20.8%) showed a recan-
alization of more than 50%. In 10 extremities (18.9%), the
venous segments remained occluded despite therapy
(Table II).
The most frequent complication was recurrent throm-
bosis, which occurred in seven extremities (13.2%). In two
cases, successful treatment of the recurrent venous occlu-
sion was possible with rethrombectomy. Three patients
(5.7%) had wound-healing problems with secondary heal-
ing of the groin wound. Bleeding complications were en-
countered in two patients (3.8%). After a postoperative
course without bleeding, a 47-year-old female patient on
postoperative day 1 had a retroperitoneal hematoma de-
velop as well as a hematothorax, both of which were most
likely from an overdose of heparin. A 72-year-old female
patient had an extensive hematoma develop in the thigh,
which had to be revised in the operating room. This patient
had had a pulmonary embolism during the initial opera-
tion, which at that time had been successfully treated with
lysis via a pulmonary catheter. Lethal complications were
not encountered. Table III shows the type and number of
complications.
DISCUSSION
The recanalization of occluded veins in DVT of the
lower extremity can be attempted with fibrinolytic4-8 or
surgical therapy.9,10 Fibrinolytic therapy, especially with
catheter-directed methods,11-13 is nowadays favored be-
cause it has the advantage of causing less damage to the
endothelium as compared with mechanical thrombecto-
my.14,15 One disadvantage of fibrinolytic therapy, how-
ever, is its low feasibility. Because of potential severe bleed-
ing complications, a strict patient selection is mandatory.
This often excludes fibrinolysis in exactly those patients
who have a high frequency of DVT, for example, patients
who were freshly operated. Therefore, in a substantial
number of patients, surgical thrombectomy is the only
therapeutic option to attempt recanalization. However, the
mechanical removal of thrombotic material from peripheral
venous segments is not without problems. In these vessels,
recanalization is usually only possible within 1 week after
Fig 2. Number and localization of thrombosed venous segments before surgery, during surgery after surgical
thrombectomy, and after surgery after thrombectomy and RHFP.
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the onset of thrombosis. After this time, the adherence of
the thrombi to the vessel wall increases and the results of
the recanalization therapy get increasingly worse.16 There-
fore, mechanical thrombectomy is usually performed up to
a clinical thrombus age of 4 to 7 days.
However, the assessment of thrombus age on the basis
of the clinical symptoms is quite unreliable. Accordingly, it
is not unusual that older, wall-adherent, and mechanically
unremovable thrombi are found during the operation of a
presumably fresh thrombosis. Residual thrombi in the pe-
ripheral venous segments cause a relative stasis of blood
flow in the neighboring vessel segments, thereby increasing
the risk of rethrombosis. Because of the therapy-resistant
thrombi and the secondary rethrombosis, the goal of recan-
alization therapy—to avoid the postthrombotic syn-
drome—is often missed.
The strong wall adherence of therapy-resistant thrombi
is the result of an organization process17 that starts soon
after the onset of thrombosis. Fibrin bridges form between
the thrombus and the inner vessel wall, causing a rigid
connection. To overcome this adherence, it is necessary to
destroy the fibrin bridges. As with arterial thrombi, intra-
operative fibrinolysis can be used to achieve this goal. The
application of fibrinolytic agents, however, is made more
difficult by the tree-like ramification of the venous
branches, which in addition can only be probed in ante-
grade fashion because of the venous valves. Because of
their, in comparison, significantly larger extent, venous
thromboses require high doses of fibrinolytics, which can-
not be applied easily in an intraoperative setting.
Creech and coworkers18 in 1956 were the first to
describe the method of isolated perfusion of an extremity
with the help of a heart-lung machine. This technique
allowed the application of aggressive and highly potent
drugs with a lower incidence of systemic side effects. With
this method in the treatment of malignant tumors, drug
levels up to 100 times higher than in systemic chemother-
apy were achieved.19 In 1978, Nachbur, Beck, and Senn20
for the first time reported the use of this method for the
intraoperative fibrinolysis of DVT of the lower extremities.
With the perfusions that lasted 60 to 80 minutes and were
conducted in normothermia, three partial and three com-
plete recanalizations were achieved. However, the authors
used extremely low concentrations of the fibrinolytic agent
of 25,000 to 30,000 IU.
In 1991, we reported the treatment of five patients with
lower extremity DVT with intraoperative ultra–high-dose
fibrinolysis with 1,000,000 IU of streptokinase.21 Accord-
ing to previous experiments that had shown that the fi-
brinolytic activity of streptokinase had an optimum at a
temperature of 40° C,22,23 the perfusions were conducted
with hyperthermia. We achieved two complete and two
partial recanalizations; one treatment failed.
Despite the isolated perfusion, the entry of the fibrino-
lytic agent into the systemic circulation cannot be avoided
completely. For a brief period of time, the plasma level of
the agent can reach levels similar to those in systemic
fibrinolysis.24 To avoid potential systemic side effects in this
setting, the antiplasmin pool of the systemic blood was
artificially elevated with the intravenous infusion of the
antifibrinolytic agent aprotinin. Aprotinin is a protease
inhibitor and has a direct inhibitory effect on circulating
plasmin, thereby acting similar to the physiologic plasmin
antagonists.25 In this way, the fibrinolytic milieu of the
perfusion circuit was opposed by an artificially created
antifibrinolytic milieu of the systemic circulation, with the
soft-tissue tourniquet in the groin acting as a “watershed”
between the two circuits. Aprotinin, which was applied in a
dose of 500,000 kallikrein inactivation units, has been used
for years in significantly higher doses in cardiac and ortho-
pedic surgery without relevant side effects. It has been
shown to lead to a marked reduction in blood consump-
tion.26,27
Compared with streptokinase, the fibrinolytic agent
rt-PA is faster acting and easier to control.28 The fibrino-
lytic activity is dose dependent and increases with elevation
of the dosage.29 An additional advantage of rt-PA is its high
affinity for fibrin-bound plasminogen. Plasmatic plasmino-
gen, which is present in the extracorporeal circuit in a lesser
extent anyway, plays only a subordinate role in the fibrino-
lysis with rt-PA.
Fibrinolysis with rt-PA is temperature dependent.
Within the physiologic temperature range, there is an al-
most linear rise in fibrinolytic activity with increasing tem-
perature.23 Because of its relatively high molecular weight
of 70,000, rt-PA cannot pass through the vessel walls and
therefore always remains intravascular. Therefore, the accu-
mulation of the active drug in the interstitial tissue, known
from locoregional chemotherapy,19 can be avoided. This
facilitates the removal of remaining intravascular rt-PA after
the perfusion. In addition, the reprocessing of the perfusion
solution in the autotransfusion set (cell saver) is facilitated
because the rt-PA is completely removed together with the
plasma. The red blood cell concentrate gained in this way is
completely free of fibrinolytic agents and can be reinfused
without problems. On the basis of these advantages, we
Table II. Recanalization success after thrombectomy and
RHFP
No.
Complete recanalization 20 (37.7%)
Partial recanalization 12 (22.6%)
Minimal recanalization (50%) 11 (20.8%)
Failed recanalization 10 (18.9%)
Table III. Complications
No.
Recurrent thrombosis 7 (13.2%)
Wound healing problems 3 (5.7%)
Bleeding complications 2 (3.8%)
Pulmonary embolism 1 (1.9%)
Mortality 0
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have used rt-PA as the fibrinolytic agent of choice since
January 1993. With a dose of 0.5 mg/kg of body weight,
levels of rt-PA of up to 20,000 ng/mL were achieved in the
perfusion solution of the extracorporeal circuit.24 These
concentrations were 70 to 100 times higher than the max-
imum levels of rt-PA of 200 to 300 ng/mL described in the
literature with systemic fibrinolysis for DVT.29
In two thirds of the cases, partially dissolved thrombi
were washed out during the fibrinolytic perfusion into the
extracorporeal circuit, where they were trapped either in
the venous perfusion catheter or in the oxygenator (Fig 3).
The embolization of thrombus fragments was definitely
enhanced by the manual compression of the thigh muscles,
which was performed during the thrombolysis to loosen
the thrombotic material. In addition, a correlation to the
ultra-high concentration of rt-PA might be possible.
Grimm, Schwieder, and Wagner30 could show that ultra–
high-dosage fibrinolytic therapy has a higher frequency of
embolization as compared with fibrinolysis with conven-
tional doses. According to the authors, ultra–high-dosage
fibrinolysis acts faster and less uniform than the conven-
tional therapy, thereby promoting embolization. Our ob-
servations confirm this theory.
In accordance with Turpie et al,8 we defined a recana-
lization with a reduction in thrombus load of less than 50%
of the initial thrombus mass as inadequate. This strict
definition allows the discrimination of minimal and thereby
insignificant recanalization. In 60.5% of our patients with
negative preselection with therapy-resistant extensive
DVT, a recanalization of more than 50% of the initial
thrombus extent was achieved. Because the severity of a
postthrombotic syndrome correlates with the extent of
recanalization documented with phlebography,31,32 we
suspect that the postthrombotic syndrome was averted or at
least alleviated in most of our patients. A definitive state-
ment, however, concerning the development of a post-
thrombotic syndrome in these patients will only be possible
after a follow-up period of 5 to 10 years.
The pharmacologic advantages of rt-PA and the intro-
duction of the antifibrinolytic protection with aprotinin led
to an improvement in the application safety of the RHFP.
None of the 53 consecutively recorded patients had severe
bleeding complications from the RHFP. The far-going
avoidance of systemic side effects allowed the use of RHFP
even in cases with contraindications for systemic fibrinoly-
sis, for example, patients who were freshly operated and
patients with gastrointestinal ulcerations. Compared with
the systemic fibrinolytic therapy of lower extremity DVT,
which has a morbidity rate of up to 38% and a mortality rate
of up to 1%33 despite strict patient selection, the RHFP
seems to have less risks and to allow a broader application.
CONCLUSION
More than 50% of initially failed surgical thrombecto-
mies could be turned into successful recanalizations with
the help of the RHFP technique. Intraoperative application
of ultra–high-dosage fibrinolysis supported by hyperther-
mia could be shown to improve the results of surgical
thrombectomy. The morbidity rate of fibrinolytic therapy
with the RHFP technique was substantially lower than the
one described with the established forms of intraoperative
fibrinolysis. Accordingly, the RHFP method improves the
safety of intraoperative fibrinolytic treatment.
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